Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies
Open Access

HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance In Vitro Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice

SEI MORINAGA, KOHEI MIZUTA, BYUNG MO KANG, QINGHONG HAN, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA and ROBERT M. HOFFMAN
In Vivo May 2025, 39 (3) 1275-1282; DOI: https://doi.org/10.21873/invivo.13931
SEI MORINAGA
1AntiCancer Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOHEI MIZUTA
1AntiCancer Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BYUNG MO KANG
1AntiCancer Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
QINGHONG HAN
1AntiCancer Inc., San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL BOUVET
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIO YAMAMOTO
3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUHIRO HAYASHI
3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROAKI KIMURA
3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINJI MIWA
3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENTARO IGARASHI
3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI HIGUCHI
3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI TSUCHIYA
3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATORU DEMURA
3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBERT M. HOFFMAN
1AntiCancer Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: all@anticancer.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Eribulin is a microtubule inhibitor used in the treatment of various malignancies, including soft-tissue sarcoma. However, the development of eribulin resistance is a recalcitrant clinical problem. The present study demonstrates that super eribulin-resistant HT1080 human fibrosarcoma cells become highly malignant but can be eradicated synergistically by the combination of eribulin and methionine restriction in nude mice.

Materials and Methods: The cell viability of parental HT1080 cells and super eribulin-resistant HT1080 was determined following eribulin treatment using the WST-8 reagent. In vitro invasion assays, comprising wound-healing of cell monolayers, were performed to determine the degree of malignancy. Tumor growth to determine malignancy and tumor-growth sensitivity to eribulin, or a methionine-restricted diet, or their combination were analyzed in athymic nude mice.

Results: The IC50 of eribulin for parental HT1080 cells was 0.15 nM, whereas for super eribulin-resistant HT1080 cells, the IC50 of eribulin was 18 nM, a 120-fold increase. Super eribulin-resistant HT1080 cells had a more rapid wound-healing closure rate in vitro than their parental HT1080 cells, indicating increased malignancy. Similarly, in vivo, untreated super eribulin-resistant HT1080 tumors grew faster than parental HT1080 tumors, confirming their high malignancy. The combination of a methionine-restricted diet and eribulin synergistically arrested super eribulin-resistant HT1080 tumors. Methionine restriction sensitized these highly resistant and malignant cells to eribulin.

Conclusion: Methionine restriction combined with eribulin represents a promising strategy to effectively treat eribulin-resistant high-malignancy fibrosarcoma, that can be immediately applied to the clinic.

Keywords:
  • HT1080
  • fibrosarcoma
  • super eribulin-resistance
  • high malignancy
  • methionine addiction
  • Hoffman effect
  • methionine restriction
  • eribulin
  • synergy
  • nude mice

Introduction

Soft tissue sarcomas (STS) are heterogeneous, but rare (1). STS which acquire drug resistance in the clinic become a recalcitrant cancer with no improvement over decades (2). Eribulin is a synthetic analog of halichondrin B, which inhibits microtubule dynamics (3) and is approved for second-line treatment for advanced STS (4).

The development of eribulin resistance significantly limits its clinical efficacy. Eribulin resistance in STS is incompletely understood and results in very poor patient prognosis with no improvements made for better therapeutic outcomes (4).

All cancer cell types, including STS, are methionine addicted, known as the Hoffman effect, relying on exogenous methionine for survival and proliferation (5-13) even though cancer cells synthesize large amounts of methionine via vitamin B-12-dependent methionine synthesase, determined in vivo and in vitro (7, 12, 13). Methionine addiction of cancer is targeted by methionine restriction (MR) by both recombinant methioninase (rMETase) and a methionine-restricted diet, or medium, in preclinical models and in the clinic (14-18).

In the present study, we developed in vitro a super eribulin-resistant HT1080 (SER-HT1080) human fibrosarcoma cell line model to investigate the effects of eribulin resistance on tumor malignancy. MR was used to overcome eribulin resistance and enhance antitumor efficacy in vivo.

Materials and Methods

Cell culture. The HT1080 human fibrosarcoma cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Grand Island, NY, USA) and 1 IU/ml penicillin/streptomycin (Thermo Fisher Scientific).

Reagents and diet. Eribulin was acquired from Eisai Inc. (Nutley, NJ, USA). The methionine-deficient diet (TD. 210562, Inotiv, Inc., West Lafayette, IN, USA) contained 1.2 g/kg L-methionine compared to 8.2g/kg L-methionine in a normal diet.

Establishment of super eribulin-resistant HT1080 cells. Super eribulin-resistant HT1080 cells (SER-HT1080) were developed by culturing parental HT1080 cells in progressively step-wise increasing concentrations (0.15-6 nM) of eribulin over six months.

IC50 determination of eribulin. Cell viability was assessed using the WST-8 reagent (Dojindo Laboratory, Kumamoto, Japan). Cells were cultured in 96-well plates (3,000 cells/well) in DMEM (100 μl/well) and incubated at 37°C overnight. Cells (HT1080 and SER-HT1080) were treated with increasing concentrations of eribulin, between 0.5 nM and 16 nM for 72 h. At the end of the culture period, 10 μl of the WST-8 solution was added to each well and the plates were additionally incubated for 1 h at 37°C. Absorbance was measured with a microplate reader (SUNRISE: TECAN, Mannedorf, Switzerland) at 450 nm. Drug sensitivity curves were obtained with Microsoft Excel for Mac 2016 ver. 15.52 (Microsoft, Redmond, USA) and half-maximal inhibitory concentration (IC50) values were calculated using ImageJ ver. 1.53k (National Institutes of Health, Bethesda, MD, USA). Experiments were performed twice, each in triplicate.

Wound healing invasion assay. HT1080 and SER-HT1080 cells were seeded in 6-well plates containing DMEM and 10% FBS and incubated overnight at 37°C. Wounds were created by scratching the cell monolayers with a 200 μl pipette tip. Subsequent to scratching, the plates were rinsed twice with phosphate-buffered saline (PBS; #MB1039-1X, BioPioneer Inc., San Diego, CA, USA) to remove detached cells, and then incubated at 37°C in DMEM with 10% FBS. The wound width was measured using light microscopy (Olympus IX71, Olympus Corporation, Tokyo, Japan) at four and eight hours after wounding. Each experiment was conducted in triplicate and repeated twice.

Mice. Athymic nu/nu nude mice (4-6 weeks) were obtained from AntiCancer Inc. (San Diego, CA, USA). All animal experiments were performed in accordance with a protocol sanctioned by the Institutional Animal Care and Use Committee (IACUC) of AntiCancer Inc. The procedures complied with the National Institutes of Health (NIH) guidelines for the Care and Use of Laboratory Animals and conformed to the ARRIVE guidelines 2.0.

Establishment of subcutaneous HT1080 tumors and SER-HT1080 tumors. Nude mice were injected in the right flank with HT1080 or SER-HT1080 cells (1×106) to induce subcutaneous tumor formation. One month after cell injection, the resultant subcutaneous tumors were excised, sectioned into 3-4 mm3 fragments, and re-implanted into the right flank of additional nude mice. Two weeks post-implantation, the tumor-bearing mice were treated as described below.

Treatment protocol. The SER-HT1080 nude mouse models were randomized into four groups once the tumor volume exceeded 100 mm3. The parental HT1080 nude mouse models were divided into two groups. Group 1: untreated control (SER-HT1080), Group 2: eribulin treated [intravenous (iv), 1.5 mg/kg (once a week, two weeks)] (SER-HT1080); Group 3: methionine-restricted diet (SER-HT1080); Group 4: eribulin treatment [iv, 1.5 mg/kg (once a week, two weeks)] plus a methionine-restricted diet (SER-HT1080); Group 5: untreated control (HT1080); Group 6 eribulin treated [iv, 1.5 mg/kg (once a week, two weeks)] (HT1080). Each group comprised five mice. Tumor volume and body weight were measured twice a week. The calculation of tumor volume was performed using the formula: tumor volume (mm)=length (mm)×width (mm)×width (mm)×1/2.

Statistical analysis. Statistical analyses were conducted using EZR software (Jichi Medical University, Saitama, Japan) (16). The relationships between variables were analyzed using the Tukey-Kramer method, with a p-value of ≤0.05 considered statistically significant.

Results

Eribulin IC50 on SER HT1080 increased 120-fold compared to parental HT1080 cells. The eribulin IC50 on HT1080 cells was 0.15 nM [data from (17)]. The eribulin IC50 of SER-HT1080 cells was 18 nM (120 fold increase) (Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Eribulin IC50 on HT1080 and super eribulin-resistant HT1080 (SER-HT1080) cells (mean±SD, n=3). A) Sensitivity of HT1080 cells to eribulin [data from (17)]. B) Sensitivity of SER-HT1080 cells to eribulin, which have a 120-fold increased eribulin IC50. Please see Materials and Methods for details.

SER-HT1080 cells acquired greater malignancy determined by 2.78 fold more rapid in vitro wound-healing compared to parental HT1080. A wound-healing assay in vitro was used to determine the invasion capability of HT1080 and SER-HT1080 cells. SER-HT1080 cells had a 2.78 fold more rapid wound repair than their parental HT1080 cells (p<0.05) (Figure 2). These results suggest that SER-HT1080 cells have a greater level of malignancy in vitro.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

In vitro wound-healing assay to determine relative malignancy of super-eribulin -resistant HT1080 (SER-HT1080) compared to parental cells. SER-HT1080 cells have more rapid wound healing than parental HT1080. A) Black lines indicate the boundaries of the wound of the cells grown in Dulbecco’s Modified Eagle’s Medium (DMEM). Wounds were made by scratching the cell monolayers with a 200 μl pipette tip. An Olympus IX71 microscope was used to observe wound closure. B) Bar graphs compare the wound closure ratio at 8 hours for HT1080 and SER-HT1080. Magnification: 40×. Scale bar: 100 μm. Please see Materials and Methods for details.

Tumor growth rate of SER-HT1080 increased 2.36-fold compared to parental HT1080 in nude mice, indicating increased malignancy. The volume of SER-HT1080 tumors without treatment increased 2.36 fold compared to parental HT1080 tumors during 14 days growth in nude mice, indicating that SER-HT1080 tumors had more malignancy (Figure 3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Comparison of super eribulin-resistant HT1080 and parental HT1080 tumor growth in nude mice. A) The volume of untreated super eribulin-resistant HT1080 (SER-HT1080) tumors increased more than HT1080 tumors (2.36-fold) over 14 days growth in nude mice. B) Bar graphs represent tumor volume of SER-HT1080 and HT1080 after 14 days growth in nude mice. These results indicate that SER-HT1080 tumors had more malignancy. Tumors were grown subcutaneously in nu/nu nude mice. Please see Materials and Methods for details.

SER-HT1080 is eribulin resistant in vivo. The volume of HT1080 tumors treated with eribulin was 4.82 fold slower compared to SER-HT1080 tumors treated with eribulin, indicating that SER-HT1080 tumors were more resistant to eribulin in vivo than parental HT1080 tumors (Figure 4).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Comparison of super eribulin-resistant and parental HT1080 tumor growth during eribulin treatment. A) Super eribulin-resistant HT1080 (SER-HT1080) tumors treated with eribulin [intravenous, 1.5 mg/kg (once a week, two weeks)] grew more than eribulin-treated HT1080 tumors in nude mice (4.82 fold) over a 14-day treatment period. B) Bar graphs represent tumor volume of eribulin-treated SER-HT1080 and HT1080 after 14 days growth in nude mice. These results indicate that SER-HT1080 tumors were more resistant to eribulin. Tumors were grown subcutaneously in nude mice. Please see Materials and Methods for details.

The combination of eribulin and methionine restriction synergistically arrested tumor growth of SER-HT1080. The combination of the methionine-restricted diet plus eribulin synergistically arrested the SER-HT1080 tumors (p<0.05 compared to all other groups) without causing more than 10% weight loss (Figure 5 and Figure 6).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Efficacy of eribulin and a methionine restricted diet (MR) and their combination on super eribulin-resistant HT1080 tumors in nude mice. A) Eribulin+methionine restriction (MR) had high synergy on super eribulin-resistant HT1080 (SER-HT1080) tumor growth in nude mice. B) Bar graphs represent tumor growth of SER-HT1080 and HT1080 at day 14, treated with eribulin or MR or their combination, showing high synergy of the combination. Tumors were grown subcutaneously in nude mice. Please see Materials and Methods for treatment protocol and other details.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Effect of eribulin or a methionine-restricted diet or their combination on body weight of nude mice with super eribulin-resistant HT1080 (SER-HT1080) and parental HT1080 tumors. Tumors were grown subcutaneously in nude mice. Please see Materials and Methods for treatment protocol and other details. Data are shown as the mean±standard deviation.

Discussion

The present study demonstrated that SER-HT1080 human fibrosarcoma cells acquire increased malignancy during in vitro selection for eribulin resistance, as shown by enhanced invasion ability in vitro and accelerated tumor growth in nude mice. These findings are consistent with previous reports that drug-resistant cancer cells often acquire more aggressive phenotypes, posing significant problems in cancer treatment (19).

We have previously shown MR and all types of chemotherapy are highly synergistic on all major types of cancer (16). Regarding HT1080, we have shown the following chemotherapy drugs are synergistic with MR: doxorubicin (20), ifosfamide (21), eribulin (17, 22), trabectedin (23, 24), gemcitabine (25) and docetaxel (26).

In the present study, the combination of MR and eribulin arrested SER-HT1080 tumor growth, indicating high synergy of MR and eribulin, suggesting a new paradigm of treating drug-resistant sarcoma.

Conclusion

The present study highlights the increased malignancy of SER-HT1080 cells and the potential of methionine restriction to overcome eribulin resistance and high malignancy. Methionine restriction, in combination with eribulin, has immediate clinical potential for eribulin-resistant soft tissue sarcoma.

Acknowledgements

This article is dedicated to the memory of A.R. Moossa, MD, Sun Lee, MD, Richard W. Erbe, MD, Professor Gordon H. Sato, Professor Li Jiaxi, Masaki Kitajima, MD, Joseph R. Bertino, MD, Shigeo Yagi, PhD, J.A.R Mead, Ph.D., Eugene P. Frenkel, MD, Professor Lev Bergelson, Professor Sheldon Penman, Professor John R. Raper, Joseph Leighton, MD and John Mendelsohn, MD. The Robert M. Hoffman Foundation for Cancer Research provided funds for the present study.

Footnotes

  • Authors’ Contributions

    SM and RMH designed the study. HQ, KM, BMK, MB, NY, KH, HK, SM, KI, TH, HT and SD critically reviewed the manuscript. SM performed experiments. SM was a major contributor to writing the manuscript and RMH revised the article. All Authors read and approved the final manuscript.

  • Conflicts of Interest

    The Authors declare no competing interests in relation to this study.

  • Received January 16, 2025.
  • Revision received February 15, 2025.
  • Accepted February 17, 2025.
  • Copyright © 2025, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. von Mehren M,
    2. Randall RL,
    3. Benjamin RS,
    4. Boles S,
    5. Bui MM,
    6. Ganjoo KN,
    7. George S,
    8. Gonzalez RJ,
    9. Heslin MJ,
    10. Kane JM,
    11. Keedy V,
    12. Kim E,
    13. Koon H,
    14. Mayerson J,
    15. McCarter M,
    16. McGarry SV,
    17. Meyer C,
    18. Morris ZS,
    19. O’Donnell RJ,
    20. Pappo AS,
    21. Paz IB,
    22. Petersen IA,
    23. Pfeifer JD,
    24. Riedel RF,
    25. Ruo B,
    26. Schuetze S,
    27. Tap WD,
    28. Wayne JD,
    29. Bergman MA,
    30. Scavone JL
    : Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(5): 536-563, 2018. DOI: 10.6004/jnccn.2018.0025
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Frezza AM,
    2. Stacchiotti S,
    3. Gronchi A
    : Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med 15(1): 109, 2017. DOI: 10.1186/s12916-017-0872-y
    OpenUrlCrossRefPubMed
  3. ↵
    1. Cortes J,
    2. Schöffski P,
    3. Littlefield BA
    : Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. Cancer Treat Rev 70: 190-198, 2018. DOI: 10.1016/j.ctrv.2018.08.008
    OpenUrlCrossRefPubMed
  4. ↵
    1. Seetharam M,
    2. Kolla KR,
    3. Chawla SP
    : Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma. Future Oncol 14(16): 1531-1545, 2018. DOI: 10.2217/fon-2017-0461
    OpenUrlCrossRefPubMed
  5. ↵
    1. Abo Qoura L,
    2. Balakin KV,
    3. Hoffman RM,
    4. Pokrovsky VS
    : The potential of methioninase for cancer treatment. Biochim Biophys Acta Rev Cancer 1879(4): 189122, 2024. DOI: 10.1016/j.bbcan.2024.189122
    OpenUrlCrossRef
    1. Lin DW,
    2. Carranza FG,
    3. Borrego S,
    4. Lauinger L,
    5. Dantas de Paula L,
    6. Pulipelli HR,
    7. Andronicos A,
    8. Hertel KJ,
    9. Kaiser P
    : Nutrient control of splice site selection contributes to methionine addiction of cancer. Mol Metab 93: 102103, 2025. DOI: 10.1016/j.molmet.2025.102103
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hoffman RM,
    2. Erbe RW
    : High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci U S A 73(5): 1523-1527, 1976. DOI: 10.1073/pnas.73.5.1523
    OpenUrlAbstract/FREE Full Text
    1. Stern PH,
    2. Hoffman RM
    : Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro 20(8): 663-670, 1984. DOI: 10.1007/BF02619617
    OpenUrlCrossRefPubMed
    1. Yamamoto J,
    2. Han Q,
    3. Inubushi S,
    4. Sugisawa N,
    5. Hamada K,
    6. Nishino H,
    7. Miyake K,
    8. Kumamoto T,
    9. Matsuyama R,
    10. Bouvet M,
    11. Endo I,
    12. Hoffman RM
    : Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells. Biochem Biophys Res Commun 533(4): 1034-1038, 2020. DOI: 10.1016/j.bbrc.2020.09.108
    OpenUrlCrossRefPubMed
    1. Yamamoto J,
    2. Inubushi S,
    3. Han Q,
    4. Tashiro Y,
    5. Sugisawa N,
    6. Hamada K,
    7. Aoki Y,
    8. Miyake K,
    9. Matsuyama R,
    10. Bouvet M,
    11. Clarke SG,
    12. Endo I,
    13. Hoffman RM
    : Linkage of methionine addiction, histone lysine hypermethylation, and malignancy. iScience 25(4): 104162, 2022. DOI: 10.1016/j.isci.2022.104162
    OpenUrlCrossRefPubMed
    1. Aoki Y,
    2. Han Q,
    3. Tome Y,
    4. Yamamoto J,
    5. Kubota Y,
    6. Masaki N,
    7. Obara K,
    8. Hamada K,
    9. Wang JD,
    10. Inubushi S,
    11. Bouvet M,
    12. Clarke SG,
    13. Nishida K,
    14. Hoffman RM
    : Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylation. Front Oncol 12: 1009548, 2022. DOI: 10.3389/fonc.2022.1009548
    OpenUrlCrossRefPubMed
  7. ↵
    1. Wang Z,
    2. Yip LY,
    3. Lee JHJ,
    4. Wu Z,
    5. Chew HY,
    6. Chong PKW,
    7. Teo CC,
    8. Ang HY,
    9. Peh KLE,
    10. Yuan J,
    11. Ma S,
    12. Choo LSK,
    13. Basri N,
    14. Jiang X,
    15. Yu Q,
    16. Hillmer AM,
    17. Lim WT,
    18. Lim TKH,
    19. Takano A,
    20. Tan EH,
    21. Tan DSW,
    22. Ho YS,
    23. Lim B,
    24. Tam WL
    : Methionine is a metabolic dependency of tumor-initiating cells. Nat Med 25(5): 825-837, 2019. DOI: 10.1038/s41591-019-0423-5
    OpenUrlCrossRefPubMed
  8. ↵
    1. Sullivan MR,
    2. Darnell AM,
    3. Reilly MF,
    4. Kunchok T,
    5. Joesch-Cohen L,
    6. Rosenberg D,
    7. Ali A,
    8. Rees MG,
    9. Roth JA,
    10. Lewis CA,
    11. Vander Heiden MG
    : Methionine synthase is essential for cancer cell proliferation in physiological folate environments. Nat Metab 3(11): 1500-1511, 2021. DOI: 10.1038/s42255-021-00486-5
    OpenUrlCrossRef
  9. ↵
    1. Sato M,
    2. Han Q,
    3. Mori R,
    4. Mizuta K,
    5. Kang BM,
    6. Morinaga S,
    7. Kobayashi N,
    8. Ichikawa Y,
    9. Nakajima A,
    10. Hoffman RM
    : Reduction of tumor biomarkers from very high to normal and extensive metastatic lesions to undetectability in a patient with stage IV HER2-positive breast cancer treated with low-dose trastuzumab deruxtecan in combination with oral recombinant methioninase and a low-methionine diet. Anticancer Res 44(4): 1499-1504, 2024. DOI: 10.21873/anticanres.16946
    OpenUrlAbstract/FREE Full Text
    1. Sato M,
    2. Han Q,
    3. Mizuta K,
    4. Mori R,
    5. Kang BM,
    6. Morinaga S,
    7. Kobayashi N,
    8. Ichikawa Y,
    9. Nakajima A,
    10. Hoffman RM
    : Extensive shrinkage and long-term stable disease in a teenage female patient with high-grade glioma treated with temozolomide and radiation in combination with oral recombinant methioninase and a low-methionine diet. In Vivo 38(3): 1459-1464, 2024. DOI: 10.21873/invivo.13591
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Kubota Y,
    2. Han Q,
    3. Aoki Y,
    4. Masaki N,
    5. Obara K,
    6. Hamada K,
    7. Hozumi C,
    8. Wong ACW,
    9. Bouvet M,
    10. Tsunoda T,
    11. Hoffman RM
    : Synergy of combining methionine restriction and chemotherapy: the disruptive next generation of cancer treatment. Cancer Diagn Progn 3(3): 272-281, 2023. DOI: 10.21873/cdp.10212
    OpenUrlCrossRefPubMed
  11. ↵
    1. Morinaga S,
    2. Han Q,
    3. Kubota Y,
    4. Mizuta K,
    5. Kang BM,
    6. Sato M,
    7. Bouvet M,
    8. Yamamoto N,
    9. Hayashi K,
    10. Kimura H,
    11. Miwa S,
    12. Igarashi K,
    13. Higuchi T,
    14. Tsuchiya H,
    15. Hoffman RM
    : Extensive synergy between recombinant methioninase and eribulin against fibrosarcoma cells but not normal fibroblasts. Anticancer Res 44(3): 921-928, 2024. DOI: 10.21873/anticanres.16886
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Stern PH,
    2. Hoffman RM
    : Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 76(4): 629-639, 1986. DOI: 10.1093/jnci/76.4.629
    OpenUrlCrossRefPubMed
  13. ↵
    1. Croix BS,
    2. Flørenes VA,
    3. Rak JW,
    4. Flanagan M,
    5. Bhattacharya N,
    6. Slingerland JM,
    7. Kerbel RS
    : Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2(11): 1204-1210, 1996. DOI: 10.1038/nm1196-1204
    OpenUrlCrossRefPubMed
  14. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Sato M,
    6. Bouvet M,
    7. Yamamoto N,
    8. Hayashi K,
    9. Kimura H,
    10. Miwa S,
    11. Igarashi K,
    12. Higuchi T,
    13. Tsuchiya H,
    14. Demura S,
    15. Hoffman RM
    : Recombinant methioninase is selectively synergistic with doxorubicin against wild-type fibrosarcoma cells compared to normal cells and overcomes highly-doxorubicin-resistant fibrosarcoma. Anticancer Res 44(8): 3261-3268, 2024. DOI: 10.21873/anticanres.17144
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Bouvet M,
    6. Yamamoto N,
    7. Hayashi K,
    8. Kimura H,
    9. Miwa S,
    10. Igarashi K,
    11. Higuchi T,
    12. Tsuchiya H,
    13. Demura S,
    14. Hoffman RM
    : Synergistic eradication of fibrosarcoma with acquired ifosfamide resistance using methionine restriction combined with ifosfamide in nude-mouse models. In Vivo 39(1): 120-126, 2025. DOI: 10.21873/invivo.13809
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Sato M,
    6. Bouvet M,
    7. Yamamoto N,
    8. Hayashi K,
    9. Kimura H,
    10. Miwa S,
    11. Igarashi K,
    12. Higuchi T,
    13. Tsuchiya H,
    14. Demura S,
    15. Hoffman RM
    : Recombinant methioninase increases eribulin efficacy 16-fold in highly eribulin-resistant HT1080 fibrosarcoma cells, demonstrating potential to overcome the clinical challenge of drug-resistant soft-tissue sarcoma. Anticancer Res 44(9): 3777-3783, 2024. DOI: 10.21873/anticanres.17202
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Morinaga S,
    2. Han Q,
    3. Kubota Y,
    4. Mizuta K,
    5. Kang BM,
    6. Sato M,
    7. Bouvet M,
    8. Yamamoto N,
    9. Hayashi K,
    10. Kimura H,
    11. Miwa S,
    12. Igarashi K,
    13. Higuchi T,
    14. Tsuchiya H,
    15. Demura S,
    16. Hoffman RM
    : DNA-binding agent trabectedin combined with recombinant methioninase is synergistic to decrease fibrosarcoma cell viability and induce nuclear fragmentation but not synergistic on normal fibroblasts. Anticancer Res 44(6): 2359-2367, 2024. DOI: 10.21873/anticanres.17043
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Sato M,
    6. Bouvet M,
    7. Yamamoto N,
    8. Hayashi K,
    9. Kimura H,
    10. Miwa S,
    11. Igarashi K,
    12. Higuchi T,
    13. Tsuchiya H,
    14. Demura S,
    15. Hoffman RM
    : Overcoming high trabectedin resistance of soft-tissue sarcoma with recombinant methioninase: a potential solution of a recalcitrant clinical problem. Anticancer Res 44(9): 3785-3791, 2024. DOI: 10.21873/anticanres.17203
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Bouvet M,
    6. Yamamoto N,
    7. Hayashi K,
    8. Kimura H,
    9. Miwa S,
    10. Igarashi K,
    11. Higuchi T,
    12. Tsuchiya H,
    13. Demura S,
    14. Hoffman RM
    : Elevated-c-MYC-expressing fibrosarcoma cells with acquired gemcitabine resistance remain sensitive to recombinant methioninase: a potential clinical strategy for a recalcitrant disease. Cancer Diagn Progn 5(1): 8-14, 2025. DOI: 10.21873/cdp.10405
    OpenUrlCrossRefPubMed
  20. ↵
    1. Morinaga S,
    2. Han Q,
    3. Mizuta K,
    4. Kang BM,
    5. Bouvet M,
    6. Yamamoto N,
    7. Hayashi K,
    8. Kimura H,
    9. Miwa S,
    10. Igarashi K,
    11. Higuchi T,
    12. Tsuchiya H,
    13. Demura S,
    14. Hoffman RM
    : Selective synergy of recombinant methioninase plus docetaxel against docetaxel-resistant and -sensitive fibrosarcoma cells compared to normal fibroblasts. Anticancer Res 44(12): 5207-5213, 2024. DOI: 10.21873/anticanres.17347
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

In Vivo: 39 (3)
In Vivo
Vol. 39, Issue 3
May-June 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance In Vitro Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance In Vitro Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice
SEI MORINAGA, KOHEI MIZUTA, BYUNG MO KANG, QINGHONG HAN, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA, ROBERT M. HOFFMAN
In Vivo May 2025, 39 (3) 1275-1282; DOI: 10.21873/invivo.13931

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance In Vitro Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice
SEI MORINAGA, KOHEI MIZUTA, BYUNG MO KANG, QINGHONG HAN, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA, ROBERT M. HOFFMAN
In Vivo May 2025, 39 (3) 1275-1282; DOI: 10.21873/invivo.13931
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Human fibrosarcoma cells selected for very-high doxorubicin resistance, acquire trabectedin and eribulin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression
  • Google Scholar

More in this TOC Section

  • In Vivo Antitumor Activity of Allicin in a Pediatric Neuroblastoma Patient-derived Xenograft (PDX) Mouse Model
  • Gefitinib Facilitates Bone Fracture Healing via Inhibition of the EGFR Pathway and Counteracting SOX9-driven Bone Metabolic Reprogramming
  • Over-expression of Truncated IK Ameliorates Dinitrochlorobenzene-Induced Allergic Contact Dermatitis Lesions in BALB/c Mice
Show more Experimental Studies

Similar Articles

Keywords

  • HT1080
  • fibrosarcoma
  • super eribulin-resistance
  • high malignancy
  • methionine addiction
  • Hoffman effect
  • Methionine restriction
  • eribulin
  • synergy
  • nude mice
In Vivo

© 2025 In Vivo

Powered by HighWire